Heart failure (HF) is a major cardiovascular syndrome with heterogeneous pathophysiology, and dyslipidemia may contribute to its development and progression through atherosclerotic, inflammatory, endothelial, and metabolic mechanisms. This narrative review aimed to evaluate the relationship between lipid disorders and HF, with particular emphasis on the potential role of statin therapy in different HF phenotypes. A literature search was conducted using PubMed, Google Scholar, and Scopus, and relevant original articles, randomized controlled trials, observational studies, systematic reviews, meta-analyses, and clinical guidelines published in English between 2000 and 2025 were reviewed. Available evidence indicates that the effects of statins in HF are phenotype- and stage-dependent. Large randomized trials did not demonstrate significant mortality benefit in advanced HF, es pecially in patients with reduced ejection fraction. However, observational studies and meta-analyses suggest potential benefit in selected subgroups, including patients with earlier-stage HF, ischemic heart disease, left ventricular ejection fraction ≥40%, type 2 diabetes, and chronic kidney disease not requiring dialysis. These effects may be partly explained by the pleiotropic anti-inflammatory, antioxidative, and endothelial-protective properties of statins. In conclusion, statin therapy does not appear to provide uniform benefit across all HF populations, but it may have clinical value in selected patients, particularly in earlier disease stages and in metabolically driven HF phenotypes.